Health & Diseases

Hemangiosarcoma in Dogs: Symptoms, Treatment & Prognosis

Hemangiosarcoma (HSA) is a highly malignant tumor of blood vessel walls (endothelial cells). It grows quickly, metastasizes early, and is often only discovered when a tumor-related internal hemorrhage—often from a ruptured spleen or a heart atrial tumor—triggers a life-threatening emergency.

Hemangiosarcoma in dogs: symptoms, treatment & prognosis

What is hemangiosarcoma in dogs?

Hemangiosarcoma (HSA) is a highly malignant tumor of the blood vessel walls (endothelial cells). It grows quickly, metastasizes early, and is often only discovered when tumor-related internal bleeding — often from a ruptured spleen or an atrial tumor — causes a life-threatening emergency.

Hemangiosarcoma is one of the most common malignant tumors in dogs. It primarily affects older dogs of medium to large breeds — Golden Retrievers, Labrador Retrievers, German Shepherds, and Boxers in particular show an increased incidence.

Background + scientific context

Schultheiss (2004, Journal of Veterinary Diagnostic Investigation, PubMed 15053370) analyzed retrospective visceral and non-visceral hemangiosarcomas and hemangiomas in domestic animals: Visceral HSA in dogs most commonly affects the spleen (>50% of cases), followed by the right atrium and liver. Non-visceral cutaneous HSA has a significantly better prognosis than visceral forms. Diagnosis is made histopathologically — imaging procedures (ultrasound, X-ray) show masses, but do not confirm the diagnosis.

Thamm (2013, Withrow & MacEwen's Small Animal Clinical Oncology, Elsevier) provided a comprehensive description of the biology and treatment of HSA: HSA tends to metastasize early via the bloodstream — the lungs, liver, omentum, and brain are common sites of metastasis. Even after surgical resection of an isolated splenic HSA lesion, median survival without chemotherapy is about 1–2 months; with adjuvant doxorubicin chemotherapy, 4–6 months. Overall, the prognosis is poor.

Batschinski et al. (2018, Veterinary and Comparative Oncology, PubMed 29115027) compared surgical treatment alone vs. surgery plus doxorubicin for visceral HSA: The combined treatment significantly prolonged median survival (surgery alone: 19 days; surgery + doxorubicin: 133 days). Important: Despite treatment, the majority of dogs died within 6 months from tumor progression or metastases. The decision for or against chemotherapy is a balance between quality of life, life expectancy, and the burden on the patient.

Vitomalia Position

Hemangiosarcoma confronts dog owners with one of the most difficult decisions: emergency surgery followed by chemotherapy — or palliative support? There is no wrong decision. What matters is making this decision consciously and with full information — together with a veterinarian who communicates the prognosis clearly and without sugarcoating it.

When does hemangiosarcoma become relevant?

  • With an acute collapse episode in an older large-breed dog: internal bleeding, suspected HSA
  • With an ultrasound finding of a splenic mass or atrial mass
  • With pale mucous membranes, weakness, distended abdomen: possible splenic rupture
  • In breeds with a known increased incidence: Golden Retriever, Labrador, German Shepherd
  • At diagnosis: decision on emergency surgery, follow-up care, chemotherapy, palliative care

Practical application

HSA — locations and prognosis:

Location Frequency Median survival time
Spleen >50% of cases 1–2 mo. (surgery alone) / 4–6 mo. (surgery + chemo)
Right atrium ~25% 1–4 months
Liver ~25% Poor, often not operable
Cutaneous form (skin) Rare Better — may be curative

Diagnostic steps: 1. Abdominal ultrasound + echocardiography if suspected 2. Chest X-ray: rule out lung metastases 3. Blood count: anemia, schistocytes (indicator of DIC) 4. Histopathology after surgery for confirmation

Common mistakes & myths

  • “After surgery, everything is fine." Surgical resection is not a curative procedure for visceral HSA — statistically, micrometastases are almost always already present.
  • “My dog had no symptoms." HSA often grows without symptoms until rupture. Regular preventive ultrasound examinations in at-risk breeds can detect findings earlier.
  • “Chemotherapy is always worthwhile." The decision depends on age, general condition, degree of metastasis, and quality of life. In cases of extensive metastasis, palliative care may be the better option.

Scientific status 2026

The median survival time for visceral HSA has changed very little over the past two decades despite improved chemotherapy protocols — the biological aggressiveness of the tumor limits therapeutic progress. Immunotherapeutic approaches (antibodies, tumor vaccines) and tyrosine kinase inhibitors are being investigated in veterinary oncology. Initial studies with propranolol as an adjunct to chemotherapy show slightly prolonged survival times — the evidence is still limited.

Frequently asked questions

How long do dogs live after a hemangiosarcoma diagnosis?

Depending on location and treatment: visceral HSA (spleen) without treatment, days to weeks; with surgery alone, approx. 1–2 months; with surgery and doxorubicin chemotherapy, approx. 4–6 months. Cutaneous HSA without visceral involvement can be treated curatively. A clear discussion with your veterinarian about prognosis and quality of life is important in every case.

Which dogs have the highest risk of hemangiosarcoma?

Older dogs (>8 years) of large breeds — especially Golden Retrievers, Labrador Retrievers, German Shepherds, Boxers, and Dobermans. Male dogs may be affected slightly more often than female dogs. Genetic predisposition in Golden Retrievers is well documented.

Are there early symptoms of hemangiosarcoma?

Often no — HSA grows for a long time without symptoms. Non-specific early signs include reduced performance, occasional weakness, and a poorer general condition. Acute symptoms (collapse, pale mucous membranes, distended abdomen) often occur only when the tumor ruptures and internal bleeding develops. Regular preventive ultrasound examinations in at-risk breeds can make earlier detection possible.

Related terms

Sources & further reading

  1. Schultheiss, P. C. (2004). A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. Journal of Veterinary Diagnostic Investigation, 16(6), 522–526. https://pubmed.ncbi.nlm.nih.gov/15053370/

  2. Thamm, D. H. (2013). Miscellaneous tumors. In S. J. Withrow, D. M. Vail, & R. L. Page (Eds.), Withrow & MacEwen's Small Animal Clinical Oncology (5th ed., pp. 679–688). Elsevier. ISBN 9781437707236.

  3. Batschinski, K., Nobre, A., Vargas-Mendez, E., Tedardi, M. V., Cirillo, J. V., Ubukata, R., Castanheira, T. L., & Dagli, M. L. Z. (2018). Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin. Veterinary and Comparative Oncology, 16(1), E169–E175. https://pubmed.ncbi.nlm.nih.gov/29115027/

Wissenschaftliche Einordnung

Schultheiss (2004, Journal of Veterinary Diagnostic Investigation, PubMed 15053370) analyzed retrogressive visceral and non-visceral hemangiosarcomas and hemangiomas in domestic animals: Canine visceral HSA most commonly affects the spleen (>50% of cases), followed by the right atrium and liver. Non-visceral cutaneous HSA has a significantly better prognosis than visceral forms. Diagnosis is histopathological — imaging techniques (ultrasound, X-ray) show space-occupying lesions but do not confirm the diagnosis.

Thamm (2013, Withrow & MacEwen's Small Animal Clinical Oncology, Elsevier) comprehensively described the biology and therapy of HSA: HSA tends to metastasize hematogenously early – the lungs, liver, omentum, and brain are common sites of metastasis. Even after surgical resection of an isolated splenic HSA lesion, the median survival time without chemotherapy is approximately 1–2 months; with adjuvant doxorubicin chemotherapy, it is 4–6 months. The overall prognosis is unfavorable.

Batschinski et al. (2018, Veterinary and Comparative Oncology, PubMed 29115027) compared surgical treatment alone vs. surgery plus doxorubicin for visceral HSA: Combined treatment significantly extended median survival (surgery alone: 19 days; surgery + doxorubicin: 133 days). Important: The majority of dogs died within 6 months despite treatment due to tumor progression or metastasis. The decision for or against chemotherapy is a balance between quality of life, life expectancy, and patient burden.